Translumina has announced the acquisition of Munich-based Lamed GmbH, which the company says moves it closer to its goal to provide a “comprehensive cardiovascular portfolio at scale across key markets globally”.
Established in 1989, Lamed is a market access platform of vascular and cardiovascular products and covers more than 1,000 hospitals in Germany, which is described by Translumina as the largest interventional cardiology market in Europe. The company distributes a portfolio of differentiated products for an international supplier base. Translumina intends to leverage the platform to introduce a portfolio of owned and partnered products in the German market.
Lazaros Ayvatoglou, the founder of Lamed, said: “After the initial discussion, it was clear that both businesses enrich each other with manifold growth opportunities. I am happy to have found a partner that builds on the established foundation of Lamed for a successful future.”
“This acquisition is of strategic importance and gives us significant access in vascular and cardiovascular markets in Germany, which is one of the largest in Europe. The synergy of our unique technologies and market penetration of Lamed shall create a formidable business opportunity for us,” said Gurmit Singh Chugh who along with Punita Sharma founded Translumina in 2010.
Arjun Oberoi, Managing Director, Everstone Capital, said: “Translumina’s acquisition of Lamed positions us for accelerated growth in Germany’s thriving peripheral interventional and vascular surgery sector. With access to major GPOs and hospitals in the largest European medical devices market, we are poised to excel in interventional cardiology, peripheral vascular, and structural heart disease segments.”
